

# Inhibition and Promotion of Angio- and Arteriogenesis

## Regulatory function of miRNA-100 via mTOR

Albert-Ludwigs-Universität Freiburg



UNI  
FREIBURG

## Technology

RNA-interference (RNAi) is a RNA dependent gene silencing process. MicroRNAs (miRNAs) are short, non-coding RNAs which regulate protein expression by imperfect mRNA base-pairing, hence inhibition of the target gene. These miRNA are found in all eukaryotic cells and it has become clear that changes in expression levels of several miRNAs are linked to various cancer types, cardiovascular diseases and inflammatory processes. For the first time we recently showed that miRNA-100 has a regulatory function in angiogenesis and arteriogenesis, also we showed that this anti-proliferative function of miRNA-100 is based on direct inhibition of the kinase mTOR (FRAP1) that is important for cellular growth, proliferation and survival.

### Innovation

- Overexpression of miRNA-100 leads to decreased levels of mTOR and reduced blood vessel growth
- Antagonistic inhibition of miRNA-100 causes stimulated endothelial proliferation, increased angiogenesis and increased levels of mTOR
- Deletion of of miRNA-100 binding site for mTOR reversed inhibition of proliferation

### Application

- Medical application of miRNA-100 mimicking compounds against tumor progression, as endogenous miRNA-100 is decreased in ovarian and endometrial cancer, metastatic prostate cancer and hepatoblastoma.
- Application of miRNA-100 inhibiting compounds ("Antagomirs") to stimulate collateral artery growth in cardiovascular disease.
- New approach to regulate angiogenesis and arteriogenesis in mTOR related diseases
- Direct impact on cellular growth and proliferation
- As miRNA-based therapeutics imitates the natural microRNA, they have the potential of fewer side effects compared to classical pharmaceuticals (e.g. rapamycin).

### Market Potential

- Cardiovascular disease and Cancer are the first and second most frequent causes of death in industrial nations and angiogenesis plays a crucial role in both pathologies.
- Increasing relevance for miRNAs in therapy and diagnosis
- Presumably relevant for treatment of mTOR-related diseases, like transplant rejection, renal failure or in-stent restenosis.

### Responsible Scientist

Dr. Sebastian Grundmann

Dept. Internal Medicine III  
(Cardio- & Angiology)

### Branch

Pharma,  
Oncology, Cardiovascular

### Patent Status

European patent application  
and PCT pending

Filed (PRD) Nov. 27<sup>th</sup>, 2009

### Reference Number

ZEE20090121

Stand: Mai-11

## Contact

Campus Technologies Freiburg GmbH | Stefan-Meier-Str. 8 | D-79104 Freiburg  
Email: [Claudia.Skamel@campus-technologies.de](mailto:Claudia.Skamel@campus-technologies.de)  
Tel: +49 (0)761 203-4987  
Fax: +49 (0)761 203-5021



# MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells

Sebastian Grundmann, M.D., Ph.D.\*, Felix P. Hans\*, Sheena Kinniry, B.Sc.\*, Jennifer Heinke, Ph.D.\*, Thomas Helbing, M.D.\*, Franziska Bluhm\*, Joost P.G. Sluijter, Ph.D.#, Imo Hofer, M.D., Ph.D.#, Gerard Pasterkamp, M.D., Ph.D.#, Christoph Bode, M.D.\* and Martin Moser, M.D.\*

\*Department of Internal Medicine III, University Hospital Freiburg, Germany  
#Laboratory of Experimental Cardiology, UMC, University of Utrecht, The Netherlands  
Contact: sebastian.grundmann@uniklinik-freiburg.de




## Introduction

The adaptive growth of blood vessels is an important protective mechanism in cardiovascular disease. However, the underlying regulatory mechanisms of this process are only partly understood. Recently, small endogenous RNAs (microRNAs) were found to play an important role in embryonic and postnatal vascular development. Here, we used microRNA-transcriptome analysis following induction of hindlimb ischemia in mice to screen for microRNAs involved in adaptive blood vessel growth following arterial occlusion.


## Methods and Results

Using microRNA-arrays, we explored the microRNA-expression profile during adaptive neovascularization. We show that the microRNA-100 is significantly downregulated after induction of hindlimb ischemia in mice. It is expressed in endothelial and vascular smooth muscle cells and has inhibitory effects on neovascularization in vitro and in vivo involving the regulation of its target gene mTOR.

### Figure 1: MiR-100 expression after induction of hindlimb ischemia




### Figure 2: MiR-100 regulates angiogenic sprouting and proliferation of vascular cells




A: Pre-miR-100 attenuates angiogenic tube formation in the planar matrigel assay

B: Pre-miR-100 inhibited endothelial sprouting.



**Figure 3: Identification of miR-100 target genes** Among the 581 significantly downregulated genes with a more than 1.5 fold decrease in expression following pre-miR-100 overexpression were 8 miRNAs with a miR-100 target site predicted. We chose mammalian target of rapamycin because of its known pro-angiogenic properties.

### Figure 4: mTOR is a miR-100 target in endothelial cells




**Figure 4: mTOR is a miR-100 target in endothelial cells** miR-100 overexpression in endothelial cells results in a decrease in mTOR expression on both mRNA (A) and protein level (B). Immuno-fluorescent staining for mTOR in endothelial cells (C) also shows a decrease.

### Figure 5: mTOR, being a miR-100 target, confers its effect on cell proliferation

Expression of ORF-mTOR, lacking the 3'-UTR miR-100 binding site, but not FL-mTOR, including the miR-100 binding site, rescues the miR-100 effect on proliferation completely.


Data are mean  $\pm$  SEM and represent mean values from at least three experiments. \* $p < 0.05$  vs. the corresponding control. ORF=open reading frame, FL=full length.

**Figure 6: miR-100 inhibition by antagomir treatment stimulates perfusion restoration following hindlimb ischemia in vivo.**



**Figure 7: mTOR inhibition attenuates perfusion restoration after femoral artery ligation and abrogates the stimulatory effect of miR-100 inhibition.**

**Figure 7: mTOR inhibition attenuates perfusion restoration after femoral artery ligation and abrogates the stimulatory effect of miR-100 inhibition.**



**Figure 7: mTOR inhibition attenuates perfusion restoration after femoral artery ligation and abrogates the stimulatory effect of miR-100 inhibition.**

## Conclusion

Our data demonstrates that miR-100 has an anti-angiogenic function and represses mTOR-signalling in endothelial and vascular smooth muscle cells. Inhibition of miR-100 could be a novel approach for the modulation of blood vessel growth and other mTOR-dependent processes.